Cladribine therapy in a patient with an aleukemic subvariant of mast cell leukemia

Charité Universitätsmedizin Berlin, Berlín, Berlin, Germany
Annals of Hematology (Impact Factor: 2.4). 11/2005; 84(10):692-3. DOI: 10.1007/s00277-005-1057-x
Source: PubMed
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Immediately following the 2010 annual American Society of Hematology (ASH) meeting, the 5th International Post-ASH Symposium on Chronic Myelogenous Leukemia and BCR-ABL1-Negative Myeloproliferative Neoplasms (MPNs) took place on 7-8 December 2010 in Orlando, Florida, USA. During this meeting, the most recent advances in laboratory research and clinical practice, including those that were presented at the 2010 ASH meeting, were discussed among recognized authorities in the field. The current paper summarizes the proceedings of this meeting in BCR-ABL1-negative MPN. We provide a detailed overview of new mutations with putative epigenetic effects (TET oncogene family member 2 (TET2), additional sex comb-like 1 (ASXL1), isocitrate dehydrogenase (IDH) and enhancer of zeste homolog 2 (EZH2)) and an update on treatment with Janus kinase (JAK) inhibitors, pomalidomide, everolimus, interferon-α, midostaurin and cladribine. In addition, the new 'Dynamic International Prognostic Scoring System (DIPSS)-plus' prognostic model for primary myelofibrosis (PMF) and the clinical relevance of distinguishing essential thrombocythemia from prefibrotic PMF are discussed.
    Blood Cancer Journal 03/2011; 1(3):e7. DOI:10.1038/bcj.2011.4 · 2.88 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Mast cell leukemia (MCL) is a very rare form of aggressive systemic mastocytosis accounting for less than 1% of all mastocytosis. It may appear de novo or secondary to previous mastocytosis and shares more clinicopathological aspects with systemic mastocytosis than with acute myeloid leukemia. Symptoms of mast cell activation, involvement of the liver, spleen, peritoneum, bones and marrow are frequent. Diagnosis is based on the presence of ≥ 20% atypical mast cells in the marrow or ≥ 10% in the blood; however, an aleukemic variant is frequently encountered in which the number of circulating MCs is < 10%. The common phenotypic features of pathologic mast cells encountered in most forms of mastocytosis are unreliable in MCL. Unexpectedly, non KIT D816V mutations are frequent and therefore, complete gene sequencing is necessary. Therapy usually fails and the median survival time is less than 6 months. The role of combination therapies and bone marrow transplantation needs further investigation.
    Blood 12/2012; DOI:10.1182/blood-2012-07-442400 · 9.78 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The clinical presentation of mastocytosis is diverse, and patients may not fit the classical description. Diagnosis requires a bone marrow examination, including immunohistochemical stains for mast cell tryptase or CD117. The treatment of adult systemic mastocytosis is highly individualized. This article presents an overview of systemic mastocytosis and describes its pathogenesis and treatment.
    Hematology/oncology clinics of North America 10/2012; 26(5):1117-28. DOI:10.1016/j.hoc.2012.08.001 · 2.07 Impact Factor